REE Automotive enters May with a corporate story that changed materially in the final days of April. The company launched a strategic alternatives review — including a potential sale — on May 1, even as its full-year numbers confirmed the severity of the challenge: roughly $1.3M in 2025 revenue against an operating loss north of $106M, with going-concern language still prominent in the filings.
The short-selling community appears to have read the room early. Short interest fell 32% across the week to just 0.77% of free float as of April 30 — well below the level where it constitutes a primary story in its own right. In raw share terms, positions dropped from around 323,000 shares in mid-to-late April to 220,000 by month-end. That unwind began sharply around April 23, the day after positions had been running at their highest levels of the recent period. Cost to borrow nearly doubled over the week to 1.58%, a notable move but still modest in absolute terms — well within normal ranges for a micro-cap Nasdaq name. With availability running above 1,000% of outstanding short interest, the lending market is loose. There is no squeeze dynamic at work here. Shorts retreating into a strategic review announcement is consistent with an orderly position reduction rather than forced covering.
The options market adds limited colour. The put/call ratio of 0.019 is fractionally above its 20-day average and about 1.5 standard deviations above the mean — but the absolute level is so low that the signal is statistical noise rather than a genuine positioning shift. Open interest in REE options is thin, and the 52-week high PCR of 0.027 reflects how sparse the options activity is. The more meaningful read on sentiment sits in the institutional register.
Ownership is concentrated and the strategic review changes its significance. Samvardhana Motherson International holds 18.3% of shares, and M&G Investment Management carries another 14.8%. Together, those two positions account for roughly a third of the company. Potomac Capital Management and Citadel both added new or materially enlarged positions as of December 2025 reporting — small in absolute size but worth noting in the context of a company now explicitly exploring a sale. Whether those recent entries reflect speculative positioning ahead of a transaction or routine portfolio allocation is not discernible from the filing dates alone.
Analyst coverage is stale and the headline numbers are difficult to reconcile with any conventional valuation framework. The most recent actions visible in the data — a $15 target maintained by HC Wainwright, an $8.50 initiation by Alliance Global Partners, and a $4 Underweight from Wells Fargo — all date from 2024 or early 2025. With the stock trading at $0.555 and a market cap below $16M, none of those targets carry meaningful current weight. The negative earnings yield, sub-1x price-to-book, and the near-zero EV/EBITDA figure all reflect a company whose valuation is now primarily a function of its optionality around the strategic review process rather than any earnings-based metric.
Prior earnings prints are a useful reference for volatility expectations. The March 2026 result produced a 2.7% one-day gain and a 15.7% five-day rally — consistent with a short-term relief bounce. The December 2025 event was the mirror image: -8.2% on the day, recovering only fractionally over the following week. Next scheduled earnings land in mid-June. The more immediate catalyst is the strategic alternatives process itself: any update on buyer interest, a signed letter of intent, or a termination of the review will be the principal driver of price action in the weeks ahead.
See the live data behind this article on ORTEX.
Open REE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
